Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aadi Bioscience, Inc. (AADI : NSDQ)
 
 • Company Description   
Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES.

Number of Employees: 39

 
 • Price / Volume Information   
Yesterday's Closing Price: $14.79 Daily Weekly Monthly
20 Day Moving Average: 116,506 shares
Shares Outstanding: 20.94 (millions)
Market Capitalization: $309.73 (millions)
Beta: 1.57
52 Week High: $49.80
52 Week Low: $11.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.65% 5.50%
12 Week -14.80% -4.25%
Year To Date -38.76% -25.18%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
17383 SUNSET AVENUE SUITE A250
-
PACIFIC PALISADES,CA 90272
USA
ph: 424-473-8055
fax: -
investors@aerpio.com http://aadibio.com
 
 • General Corporate Information   
Officers
Neil Desai - Chief Executive Officer
Caley Castelein - Chairman
Scott Giacobello - Chief Financial Officer and Principal Financial an
Emma Reeve - Director
Behzad Aghazadeh - Director

Peer Information
Aadi Bioscience, Inc. (CORR.)
Aadi Bioscience, Inc. (RSPI)
Aadi Bioscience, Inc. (CGXP)
Aadi Bioscience, Inc. (BGEN)
Aadi Bioscience, Inc. (GTBP)
Aadi Bioscience, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00032Q104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 20.94
Most Recent Split Date: 8.00 (0.07:1)
Beta: 1.57
Market Capitalization: $309.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.85 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.49
Price/Cash Flow: 8.10
Price / Sales: -
EPS Growth
vs. Year Ago Period: 26.63%
vs. Previous Quarter: 14.29%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 130.70%
ROE
03/31/22 - -42.21
12/31/21 - -40.42
09/30/21 - -47.50
ROA
03/31/22 - -37.27
12/31/21 - -36.06
09/30/21 - -37.96
Current Ratio
03/31/22 - 11.78
12/31/21 - 9.90
09/30/21 - 14.01
Quick Ratio
03/31/22 - 11.77
12/31/21 - 9.90
09/30/21 - 14.01
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -3,582.37
12/31/21 - -9,829.29
09/30/21 - -
Book Value
03/31/22 - 5.95
12/31/21 - 6.53
09/30/21 - 7.23
Inventory Turnover
03/31/22 - 3.54
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©